Irinotecan News and Research

RSS
Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.
BioAlliance Pharma to discuss nanoparticle technology and its therapeutic applications at the French-Norwegian Interdisciplinary Symposium

BioAlliance Pharma to discuss nanoparticle technology and its therapeutic applications at the French-Norwegian Interdisciplinary Symposium

Chk1 and Fbx6 play an important role for the regulation of response to chemotherapy

Chk1 and Fbx6 play an important role for the regulation of response to chemotherapy

Arno Therapeutics to commence Phase 1 clinical study of AR-12 in adult patients with lymphoma

Arno Therapeutics to commence Phase 1 clinical study of AR-12 in adult patients with lymphoma

BioAlliance Pharma posts revenue of €4.1 million for the first half of 2009

BioAlliance Pharma posts revenue of €4.1 million for the first half of 2009

Discovery of genetic biomarkers enable targeted personalised medication for Colorectal cancer

Discovery of genetic biomarkers enable targeted personalised medication for Colorectal cancer

Cost effectiveness study looks at potential value of new genetic test for guiding chemotherapy treatment

Cost effectiveness study looks at potential value of new genetic test for guiding chemotherapy treatment

New CDC study assesses impact of genetic testing on health outcomes

New CDC study assesses impact of genetic testing on health outcomes

Pre-emptive treatment helped curtail skin toxicity with Panitumumab

Pre-emptive treatment helped curtail skin toxicity with Panitumumab

Transarterial chemoembolization as liver cancer treatment

Transarterial chemoembolization as liver cancer treatment

Genentech submits application to FDA for Avastin in the most aggressive form of brain cancer

Genentech submits application to FDA for Avastin in the most aggressive form of brain cancer

Biothera initiates second phase of metastatic colorectal cancer trial

Biothera initiates second phase of metastatic colorectal cancer trial

Medicare overpaid for prescription drugs with new generic versions because of delay in incorporating new prices into payment calculations

Medicare overpaid for prescription drugs with new generic versions because of delay in incorporating new prices into payment calculations

Experimental chemo shows promise in treating advanced non-small cell lung cancer

Experimental chemo shows promise in treating advanced non-small cell lung cancer

Benefits of some cancer drugs exaggerated because trials were stopped early

Benefits of some cancer drugs exaggerated because trials were stopped early

Curing cancer with natural products - a case for shamans and herb women?

Curing cancer with natural products - a case for shamans and herb women?

Glioblastoma multiforme responds to new treatment

Glioblastoma multiforme responds to new treatment

Avastin shows promise for brain cancer

Avastin shows promise for brain cancer

Drug study for brain cancer shows promising results

Drug study for brain cancer shows promising results

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Gene screen patent brings 2007 Deal of Distinction Award to UChicagoTech

Gene screen patent brings 2007 Deal of Distinction Award to UChicagoTech

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.